Based on multiple prospective observational studies and discordance analyses, apoB is a more accurate marker of ASCVD risk than LDL-C or non–HDL-C. Hence, apoB is a better risk analyte to select patients for preventive therapy than non–HDL-C. Here, APOB is linked to atherosclerosis.